Loading...
WELCOME 2017-11-20T20:36:25+00:00

First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

February 22nd, 2019|0 Comments

Bexion Pharmaceuticals Announces the Opening of Phase I Part 3  FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 - Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human [...]

Dr. Ray Takigiku H onored as Finalist at the 2019 Healthcare Hero Awards

February 22nd, 2019|0 Comments

FOR IMMEDIATE RELEASE Covington, KY, February 22, 2019 - Dr. Ray Takigiku, Founder and CEO of Bexion Pharmaceuticals, Inc. was honored as a finalist in the category of “Entrepreneur” of the Year by the Cincinnati Business [...]

Bexion Pharmaceuticals, Inc. Presents Clinical Data at 2018 SNO Annual Meeting

November 19th, 2018|0 Comments

FOR IMMEDIATE RELEASE Covington, KY, November 19, 2018 - Bexion Pharmaceuticals, Inc., a clinical - stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster [...]

Bexion Pharmaceuticals is developing innovative cures for cancer.

Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.

Read More About Bexion
Clinical Trials

Clinical Trials

In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).

Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857